| Elevated risk of carrying gentamicin-resistant Escherichia coli among US poultry workers LB Price, JP Graham, LG Lackey, A Roess, R Vailes, E Silbergeld Environmental health perspectives 115 (12), 1738, 2007 | 181 | 2007 |
| The persistence of fluoroquinolone-resistant Campylobacter in poultry production LB Price, LG Lackey, R Vailes, E Silbergeld Environmental health perspectives 115 (7), 1035, 2007 | 163 | 2007 |
| Prevalence of potentially neuropathic Campylobacter jejuni strains on commercial broiler chicken products CG Hardy, LG Lackey, J Cannon, LB Price, EK Silbergeld International Journal of Food Microbiology 145 (2-3), 395-399, 2011 | 35 | 2011 |
| Quantitative benefit-risk assessment in medical product decision making: a good practices report of an ISPOR task force T Tervonen, J Veldwijk, K Payne, X Ng, B Levitan, LG Lackey, K Marsh, ... Value in Health 26 (4), 449-460, 2023 | 33 | 2023 |
| FDA’s benefit–risk framework for human drugs and biologics: role in benefit–risk assessment and analysis of use for drug approvals L Lackey, G Thompson, S Eggers Therapeutic innovation & regulatory science 55 (1), 170-179, 2021 | 25 | 2021 |
| Influence of feedstock: Air pollution and climate-related emissions from a diesel generator operating on soybean, canola, and yellow grease biodiesel LG Lackey, SE Paulson Energy & fuels 26 (1), 686-700, 2012 | 17 | 2012 |
| Applying decision analysis to inform the US Food and Drug Administration’s benefit–risk assessment of ticagrelor for primary prevention of myocardial infarction or stroke based … LG Lackey, CE Garnett, F Senatore Circulation 144 (8), 655-658, 2021 | 15 | 2021 |
| Evaluation of design-based sampling options for monitoring stream and wetland extent and distribution in California LG Lackey, ED Stein Wetlands 33 (4), 717-725, 2013 | 9 | 2013 |
| Selecting the optimum plot size for a California design-based stream and wetland mapping program LG Lackey, ED Stein Environmental monitoring and assessment 186 (4), 2599-2608, 2014 | 7 | 2014 |
| Illustrating emerging good practices for quantitative benefit-risk assessment: A hypothetical case study of systemic biologic treatments for plaque psoriasis LG Lackey, X Ng, J Veldwijk, P Thokala, B Levitan, K Payne, M Ho, ... Value in Health 26 (4), 519-527, 2023 | 4 | 2023 |
| How accurate are probability-based estimates of wetland extent? Results of a California validation study ED Stein, LG Lackey, J Brown Wetlands Ecology and Management 24 (3), 347-356, 2016 | 4 | 2016 |
| Evaluating alternative temporal survey designs for monitoring wetland area and detecting changes over time in California LG Lackey, ED Stein JAWRA Journal of the American Water Resources Association 51 (2), 388-399, 2015 | 2 | 2015 |
| Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation AG Winterstein, CLY Ewig, Y Wang, NE Smolinski, GA Toyserkani, ... Drug Safety 48 (2), 107-117, 2025 | 1 | 2025 |
| Key Opinion Leaders’ Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations A Simonetti, S Colilla, B Edwards, J Kübler, L Lackey, L Rodriguez, ... Drug Safety 47 (9), 853-868, 2024 | 1 | 2024 |
| Incorporating Prior Data in Quantitative Benefit–Risk Assessments: Case Study of a Bayesian Method S Dharmarajan, Z Yuan, YF Chen, L Lackey, S Mukhopadhyay, P Singh, ... Therapeutic Innovation & Regulatory Science 58 (3), 415-422, 2024 | 1 | 2024 |
| Technical Design for a Status & Trends Monitoring Program to Evaluate Extent and Distribution of Aquatic Resources in California ED Stein, LG Lackey Technical Report 706. Southern California Coastal Water Research Project …, 2012 | 1 | 2012 |
| Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies: CLY Ewig et al. CLY Ewig, Y Wang, NE Smolinski, GA Toyserkani, C LaCivita, L Lackey, ... Drug safety 48 (12), 1387-1397, 2025 | | 2025 |
| The Teratogenic Risk Impact and Mitigation (TRIM) Tool: Development of Scoring Weights to Prioritize Medications for Risk Management Beyond Labelling JC Maro, CLY Ewig, Y Wang, NEE Smolinski, G Toyerskani, C LaCivita, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 33, 20-20, 2024 | | 2024 |
| The Teratogenic Risk Impact and Mitigation (TRIM) Tool: Development of Explicit Criteria for Teratogenicity Risk Mitigation Programs CLY Ewig, Y Wang, NEE Smolinski, GA Toyserkani, C LaCivita, L Lackey, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 33, 19-19, 2024 | | 2024 |
| The Teratogenic Risk Impact and Mitigation (TRIM) Tool: Development of Scoring Weights to Prioritize Medications for Risk Management Beyond Labelling A Winterstein, CLY Ewig, Y Wang, NE Smolinski, GA Toyserkani, ... BIRTH DEFECTS RESEARCH 116, S54-S55, 2024 | | 2024 |
